Back to Newsroom

News from Immuno Cure (醫克生物)

Immuno Cure

#Healthcare #Medical

26 January 2026 5:45pm HKT

Immuno Cure Kicks off Phase I Clinical Study of Therapeutic DNA Vaccine for HIV in Hong Kong

Dr. Xia JIN, Co-founder and CEO of Immuno Cure, introduced ICVAX in the roadshow (Left) and on stage at the award ceremony of the competition (right).

#Healthcare #Pharma

06 October 2025 3:15pm HKT

Immuno Cure wins Grand Prize at the National GBA Entrepreneurship Competition

From left to right: Professor Bernard CHEUNG Man-yung, Chief Executive Officer of GBAICTI; Dr. Xia JIN, Chief Executive Officer of Immuno Cure; Ms. TANG Hongmei, Executive Director of BAY TRIAL

#Medical #Technology

30 July 2025 6:00pm HKT

Shenzhen and Hong Kong Join Hands to Promote the Development of the Hetao Shenzhen-Hong Kong Science & Technology Innovation Co-operation Zone

ICVAX is the result of the collaboration between Immuno Cure and Hong Kong AIDS Foundation, HKU AIDS Institute, Hong Kong Science & Technology Parks Corporation and the Shenzhen Third People’s Hospital.

#Medical #Healthcare

12 November 2024 6:05pm HKT

Immuno Cure Biotech Presents Promising Results on Phase I Clinical Trial of a Therapeutic HIV DNA Vaccine

From left to right: Dr. Li LIU, Scientific Officer of AIDS Institute of the University of Hong Kong; Mr. Tom LAU, Co-Founder of Immuno Cure; Dr. Percy CHENG, Chairman and Co-Founder of Immuno Cure; Professor Zhiwei CHEN, Director of AIDS Institute and Ch

#Medical #Healthcare

03 June 2024 6:00pm HKT

Immuno Cure’s Anti-Δ42PD1 Antibody Project Awarded HKSAR Government’s RAISe+ Scheme Funding

#Medical #Healthcare

27 July 2023 1:00pm HKT

Immuno Cure Completed US$12M First Close of Series A Financing, led by AEF GBA Fund managed by Gobi Partners GBA

Talk to Media OutReach Newswire today